We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.51%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$791M
AUM Growth
-$79M
Cap. Flow
-$79.2M
Cap. Flow %
-10.01%
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$15.4M
2
LLY icon
Eli Lilly
LLY
+$12.5M
3
EHC icon
Encompass Health
EHC
+$11.3M
4
CAH icon
Cardinal Health
CAH
+$8.16M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$6.81M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$19.8M
2
UNH icon
UnitedHealth
UNH
+$18M
3
PRCT icon
Procept Biorobotics
PRCT
+$14.6M
4
MOH icon
Molina Healthcare
MOH
+$14.4M
5
MCK icon
McKesson
MCK
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
76
DELISTED
Apellis Pharmaceuticals
APLS
$1.61M 0.2%
93,250
+65,000
+230% +$1.2M
RLAY icon
77
Relay Therapeutics
RLAY
$4.37B
$1.59M 0.2%
460,000
– –
BIIB icon
78
Biogen
BIIB
$30.6B
$1.51M 0.19%
12,000
-37,500
-76% -$4.67M
KURA icon
79
Kura Oncology
KURA
$874M
$1.44M 0.18%
250,000
+55,000
+28% +$337K
DNLI icon
80
Denali Therapeutics
DNLI
$4B
$1.4M 0.18%
100,000
– –
XNCR icon
81
Xencor
XNCR
$1.6B
$1.3M 0.16%
165,750
-30,000
-15% -$269K
DOCS icon
82
Doximity
DOCS
$4.57B
$1.29M 0.16%
+21,000
New +$1.17M
JANX icon
83
Janux Therapeutics
JANX
$1B
$1.27M 0.16%
55,127
-86,500
-61% -$2.28M
ALKS icon
84
Alkermes
ALKS
$8.29B
$1.12M 0.14%
39,000
– –
IOVA icon
85
Iovance Biotherapeutics
IOVA
$2.9B
$1.11M 0.14%
647,827
– –
ANNX icon
86
Annexon
ANNX
$883M
$1.1M 0.14%
460,000
– –
XENE icon
87
Xenon Pharmaceuticals
XENE
$6.21B
$1.1M 0.14%
35,000
– –
IMCR icon
88
Immunocore
IMCR
$1.73B
$887K 0.11%
28,278
– –
TECH icon
89
Bio-Techne
TECH
$11.2B
$772K 0.1%
+15,000
New +$754K
INMB icon
90
INmune Bio
INMB
$58.8M
$412K 0.05%
178,284
– –
AMGN icon
91
Amgen
AMGN
$226B
– –
-4,000
Closed -$1.25M
ARVN icon
92
Arvinas
ARVN
$588M
– –
-183,000
Closed -$1.28M
AVTR icon
93
Avantor
AVTR
$9.29B
– –
-47,826
Closed -$775K
BDX icon
94
Becton Dickinson
BDX
$48.9B
– –
-19,000
Closed -$4.35M
BMY icon
95
Bristol-Myers Squibb
BMY
$132B
– –
-325,000
Closed -$19.8M
ESPR
96
DELISTED
Esperion Therapeutics
ESPR
– –
-1,066,495
Closed -$1.54M
GERN icon
97
Geron
GERN
$949M
– –
-783,000
Closed -$1.24M
HUM icon
98
Humana
HUM
$46.3B
– –
-46,830
Closed -$12.4M
ICLR icon
99
Icon
ICLR
$12.8B
– –
-7,000
Closed -$1.22M
IDYA icon
100
IDEAYA Biosciences
IDYA
$3.54B
– –
-39,500
Closed -$647K
1 2 3
4
5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rhenman & Partners Asset Management held 105 positions worth $791M, down 9.1% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $79.2M in Q2 2025, closing 15 positions and reducing 37 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Cardinal Health worth $9.24M.

  • Rhenman & Partners Asset Management's largest Q2 2025 buy was Cardinal Health: 55,000 shares worth $9.24M.
  • Rhenman & Partners Asset Management added most to Danaher in Q2 2025, an estimated $15.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2025 reduction was UnitedHealth, cutting an estimated $18M.
  • Rhenman & Partners Asset Management fully exited Bristol-Myers Squibb in Q2 2025, selling an estimated $19.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 33% of its $791M portfolio in Q2 2025.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 15 in Q2 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 9.1% quarter-over-quarter to $791M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.